Program in Uterine Leiomyosarcoma in Partnership with the Briger Foundation for Oncology Research
Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynecologic cancer. Due to its aggressive behavior, uLMS generally has a poor prognosis, especially if diagnosed after metastasis.Â
SPARC partnered with the Briger Foundation for Oncology Research to identify opportunities to improve uLMS research, clinical care, and outcomes. Advancing research and clinical care for uLMS will require significant and sustained funding, and our assessment suggests that philanthropic investment is necessary to improve the funding landscape.
Our Work
Uterine Leiomyosarcoma: A Giving Smarter Guide
SPARC conducted an in-depth analysis of the scientific and clinical ecosystem surrounding uLMS. This effort culminated in a public report designed to synthesize current knowledge and illuminate areas of unmet need where philanthropic support could catalyze innovation.
